News Breaks |
|
|
| October 15, 2012 |
| 11:55 EDT |  | AMGN, AMGN, AMGN, LLY, LLY, LLY, MRK, MRK, MRK | Leerink's major pharmaceuticals and biotech analysts hold a conference call
Biotech Analyst Liang and Major Pharmaceuticals Analyst Fernandez, along with Dr. McClung, Founding Director of the Oregon Osteoporosis Center, discuss their impression of the new data on anti-sclerostin antibodies AMG785 (AMGN/UCB) and blosozumab (LLY) presented at the ASBMR Annual Meeting, thoughts on recent developments and data on Merck's odanacatib and MK-5442 on an Analyst/Industry conference call to be held on October 16 at 12 pm. |
|
|
News For AMGN;LLY;MRK From The Last 14 Days Check below for free stories on AMGN;LLY;MRK the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT | | MRK | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:24 EDT | | LLY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 17:49 EDT |  | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
|
| May 16, 2013 |
| 08:55 EDT | | MRK, LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 17:39 EDT |  | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. |
|
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 08:55 EDT | | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| May 10, 2013 |
| 11:48 EDT | | LLY, MRK | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
| |
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
| 06:53 EDT | | MRK | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says
Subscribe for More Information |
|
| May 9, 2013 |
| 16:48 EDT | | AMGN | Amgen, Zhejiang Beta Pharma announce joint venture in China
Subscribe for More Information |
|
| 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information |
|
| 07:22 EDT | | MRK | Merck awarded significant portion of UNICEF HPV vaccine tender
Subscribe for More Information |
|
| May 8, 2013 |
| 08:32 EDT | | MRK | Merck says FDA accepts biologics license application for allergy tablet
Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. |
|
| May 7, 2013 |
| 16:31 EDT | | AMGN | Amgen announces Phase 3 head-to-head study of Vectibix versus Erbitux
Subscribe for More Information |
|
|
|
|
|
